NASDAQ:BVXV - BIONDVAX PHARMA/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $5.12 -0.13 (-2.48 %) (As of 12/18/2018 11:45 AM ET)Previous Close$5.2502Today's Range$5.12 - $5.1252-Week Range$4.60 - $7.71Volume318 shsAverage Volume3,059 shsMarket Capitalization$34.64 millionP/E Ratio-2.59Dividend YieldN/ABeta0.99 ProfileDiscussionChartEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email BiondVax Pharmaceuticals Ltd., a clinical stage biopharmaceutical company, focuses on developing and commercializing immunomodulation therapies for infectious diseases primarily in Israel. Its product candidate is M-001, a synthetic peptide-based protein, which has completed Phase II clinical trials that is used for treating seasonal and pandemic strains of the influenza virus. The company was founded in 2003 and is headquartered in Ness Ziona, Israel. Receive BVXV News and Ratings via Email Sign-up to receive the latest news and ratings for BVXV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BVXV Previous Symbol CUSIPN/A Webwww.biondvax.com Phone972-8930-2529 Debt Debt-to-Equity Ratio2.95 Current Ratio20.74 Quick Ratio20.74 Price-To-Earnings Trailing P/E Ratio-2.59 Forward P/E Ratio-102.40 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.48 per share Price / Book2.06 Profitability EPS (Most Recent Fiscal Year)($1.98) Net Income$-9,960,000.00 Net MarginsN/A Return on Equity-168.28% Return on Assets-74.56% Miscellaneous Employees14 Outstanding Shares6,530,000Market Cap$34.64 million OptionableNot Optionable BIONDVAX PHARMA/S (NASDAQ:BVXV) Frequently Asked Questions What is BIONDVAX PHARMA/S's stock symbol? BIONDVAX PHARMA/S trades on the NASDAQ under the ticker symbol "BVXV." How were BIONDVAX PHARMA/S's earnings last quarter? BIONDVAX PHARMA/S (NASDAQ:BVXV) posted its quarterly earnings results on Tuesday, November, 13th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.01) by $0.10. View BIONDVAX PHARMA/S's Earnings History. When is BIONDVAX PHARMA/S's next earnings date? BIONDVAX PHARMA/S is scheduled to release their next quarterly earnings announcement on Monday, April 29th 2019. View Earnings Estimates for BIONDVAX PHARMA/S. Has BIONDVAX PHARMA/S been receiving favorable news coverage? Headlines about BVXV stock have been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. BIONDVAX PHARMA/S earned a coverage optimism score of -2.4 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an impact on the company's share price in the immediate future. Who are some of BIONDVAX PHARMA/S's key competitors? Some companies that are related to BIONDVAX PHARMA/S include Erytech Pharma (ERYP), Fennec Pharmaceuticals (FENC), Organovo (ONVO), Jounce Therapeutics (JNCE), Champions Oncology (CSBR), Idera Pharmaceuticals (IDRA), Nantkwest (NK), Pluristem Therapeutics (PSTI), Aptose Biosciences (APTO), Aevi Genomic Medicine (GNMX), Cidara Therapeutics (CDTX), BioCardia (BCDA), Brainstorm Cell Therapeutics (BCLI), Applied Genetic Technologies (AGTC) and Arsanis (ASNS). Who are BIONDVAX PHARMA/S's key executives? BIONDVAX PHARMA/S's management team includes the folowing people: Dr. Ron Babecoff, Co-Founder, CEO, Pres & Director (Age 56)Mr. Uri Ben-Or, Chief Financial Officer (Age 48)Dr. Tamar Ben Yedidia, Chief Scientific Officer (Age 54)Dr. Shimon Hassin Ph.D., Chief Operating OfficerMr. Joshua E. Phillipson, Bus. Devel. Mang. When did BIONDVAX PHARMA/S IPO? (BVXV) raised $10 million in an initial public offering (IPO) on Tuesday, May 12th 2015. The company issued 1,400,000 shares at a price of $7.32 per share. Aegis Capital Corp served as the underwriter for the IPO. How do I buy shares of BIONDVAX PHARMA/S? Shares of BVXV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is BIONDVAX PHARMA/S's stock price today? One share of BVXV stock can currently be purchased for approximately $5.12. How big of a company is BIONDVAX PHARMA/S? BIONDVAX PHARMA/S has a market capitalization of $34.64 million. The company earns $-9,960,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. BIONDVAX PHARMA/S employs 14 workers across the globe. What is BIONDVAX PHARMA/S's official website? The official website for BIONDVAX PHARMA/S is http://www.biondvax.com. How can I contact BIONDVAX PHARMA/S? BIONDVAX PHARMA/S's mailing address is 14 Einstein Street, Nes Ziona L3, 74036. The company can be reached via phone at 972-8930-2529 or via email at [email protected] MarketBeat Community Rating for BIONDVAX PHARMA/S (NASDAQ BVXV)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 93 (Vote Outperform)Underperform Votes: 92 (Vote Underperform)Total Votes: 185MarketBeat's community ratings are surveys of what our community members think about BIONDVAX PHARMA/S and other stocks. Vote "Outperform" if you believe BVXV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BVXV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/18/2018 by MarketBeat.com StaffFeatured Article: What are the Benefits of Index Funds?